v3.26.1
SEGMENT INFORMATION (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Reportable Segment Information
The following table includes information about segment revenue, significant segment expenses, and segment measure of profitability:
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Total revenues$989,708 $825,410 $1,755,916 $1,570,555 
Less:
Cost of sales202,795 150,090 397,794 301,648 
R&D expenses
Research and early pipeline85,069 95,968 172,360 186,438 
Later-stage clinical programs50,295 13,133 86,472 27,424 
Marketed products71,588 52,207 126,916 106,177 
SG&A expenses
S&M expenses142,186 122,100 267,113 224,631 
G&A expenses253,363 110,179 386,726 213,764 
Other segment expense, net (1)
139,650 41,201 168,246 84,255 
Net income$44,762 $240,532 $150,289 $426,218 
(1)Other segment expense, net during the three and six months ended June 30, 2026 and 2025 include intangible asset amortization, interest income and expense, other income, net and income tax expense.
Schedule of Disaggregation of Total Net Product Revenues by Product
The following table presents Total Revenues and disaggregates Net Product Revenues by product.
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
VOXZOGO$252,528 $221,391 $472,408 $435,145 
Metabolic Conditions (formerly Enzyme Therapies):
VIMIZIM194,371 215,424 404,575 403,770 
NAGLAZYME135,255 128,867 265,329 243,157 
PALYNZIQ135,167 105,938 224,725 199,207 
GALAFOLD(1)
105,748 — 105,748 — 
BRINEURA51,370 48,692 98,474 89,054 
ALDURAZYME43,539 56,437 80,281 105,414 
POMBILITI + OPFOLDA(1)
30,258 — 30,258 — 
KUVAN24,444 27,034 48,324 52,170 
ROCTAVIAN11,713 9,199 14,349 19,709 
Total net product revenues984,393 812,982 1,744,471 1,547,626 
Royalty and other revenues5,315 12,428 11,445 22,929 
Total revenues$989,708 $825,410 $1,755,916 $1,570,555 
(1)     The Company commenced recognizing revenue related to GALAFOLD and POMBILITI + OPFOLDA on April 27, 2026 following its acquisition of Amicus. Refer to Note 2 - Acquisitions for additional information.
Schedule of Disaggregation of Total Net Product Revenues by Geographic Region The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for the Company's commercial products sold directly by the Company, except for ALDURAZYME, which is distributed, marketed and sold exclusively by Sanofi worldwide.
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
United States$371,074 $272,554 $614,018 $514,248 
Europe297,498 243,138 516,334 472,716 
Latin America103,917 98,118 212,081 186,400 
Rest of world168,365 142,735 321,757 268,848 
Total net product revenues marketed by the Company940,854 756,545 1,664,190 1,442,212 
ALDURAZYME net product revenues marketed by Sanofi43,539 56,437 80,281 105,414 
Total net product revenues$984,393 $812,982 $1,744,471 $1,547,626 
Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers
The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented.
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Customer A13 %15 %14 %15 %
Customer B11 12 11 12 
Customer C11 11 10 11 
Total35 %38 %35 %38 %